Vertex Pharma (VRTX) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
No Surprises from Vertex (VRTX) But Piper Jaffray Moves Price Target Down to $143
January 28, 2016 7:25 AM ESTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating but lowered his price target on Vertex (NASDAQ: VRTX) to $143.00 (from $180.00) following results which offered no surprises.
Tenthoff commented, "As pre-announced, >4,500 patients began ORKAMBI in the U.S. resulting in sales of $220 million in 4Q:15;... More
